Recently, immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1 (PD-1)–programmed cell death ligand 1 (PD-L1) axis have emerged as a novel and effective strategy for non-small cell lung cancer (NSCLC) [3] and uterine cervical cancer (UCC) [4]. Here, PDCD1 is linked to non-small cell lung carcinoma.